Rituximab Linked to 10-fold Higher IBD Risk in MS
Summary
The anti-CD20 medication rituximab was linked to a nearly 10-fold higher risk for IBD in patients with MS than with other therapies, although the absolute risk remains low.
Description from Medscape.
Who is covering this
-
Rituximab Linked to 10-fold Higher IBD Risk in MS
The anti-CD20 medication rituximab was linked to a nearly 10-fold higher risk for IBD in patients with MS than with other therapies, although the absolute risk remains low.
Comments
Comments need JavaScript.